HUTCHMED (China) Limited (HCM) Friday said it will receive a milestone payment of $10 million from Takeda Pharmaceutical Company Limited (TAK) after Takeda received a national reimbursement recommendation for Fruzaqla for the treatment of colorectal cancer in Spain.
Fruzaqla, developed by HUTCHMED, has been licensed to Takeda to develop and sell globally, except in China, Hong Kong and Macau.
This is the first national reimbursement recommendation in Europe for Fruzaqla, which was approved by the European Commission in June this year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.